MRS2 and endometrial cancer: A 3-marker panel combining APOD, PSMA7 and HPT, predicted endometrial cancer with an AUC of 0.87 (0.81–0.93), sensitivity of 75% (64%–86%), specificity of 84% (75%–93%), and had the least AIC value (Table 3, Fig. 3f).